Finerenone—a selective non-steroidal mineralocorticoid receptor antagonist—has been shown to have kidney protective effects in individuals with chronic kidney disease (CKD) with type 2 ...
The orally-active drug, a non-steroidal mineralocorticoid receptor antagonist (nsMRA), is currently in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension – in other words ...
Endevica Bio Inc. has announced the spin-off of a newly created company, Abisati LLC, to develop an oral melanocortin MC4 receptor agonist, 710GO, as a weight loss therapy.
Inspra (eplerenone tablets; Pfizer, Inc., New York, NY) is an aldosterone blocker that works by binding at the mineralocorticoid receptor. It has some similarities to the potassium-sparing ...
Finerenone further reduces albuminuria in patients already on triple therapy for CKD with type 2 diabetes (SGLT2i, GLP-1 RA, ...
Background: Standard pharmacotherapy for patients with heart failure with reduced ejection fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a β-blocker, a ...
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback